mitapivat sulfate

DRUG2 trials

Sponsors

Agios Pharmaceuticals, Inc., EuroBloodNet Association

Conditions

Healthy VolunteersHereditary Red Blood Cell Disorder (Disorder)

Phase 1

Study to Evaluate the Effect of Multiple Doses of Itraconazole and Rifampin on the Single-Dose Pharmacokinetics of Mitapivat Sulfate (AG-348) in Healthy Adult Participants

CompletedNCT03991312

Agios Pharmaceuticals, Inc.Healthy Volunteers

Start: 2019-06-20End: 2019-09-10Updated: 2019-10-23

Phase 2

Safety and Efficacy of Mitapivat Sulfate in Adult Patients With Erythrocyte Membranopathies

Not yet recruitingNCT05935202

EuroBloodNet AssociationHereditary Red Blood Cell Disorder (Disorder)

Start: 2023-12-21End: 2026-12-15Target: 25Updated: 2023-12-26

Related Papers

Satisfy: A Eurobloodnet Multicenter, Single-Arm Phase 2 Trial of Mitapivat in Adult Patients with Erythrocyte Membranopathies and Congenital Dyserythropoietic Anemia Type II - Results from the 8-Week Dose-Escalation Period

Blood2024-11-051 citations

uRADAR: European Patients Referral Frame to Improve Access to New Drugs and Therapies in Ultra-Rare Anemia Disorders and Severe Hereditary Spherocytosis

Blood2024-11-05

Designing a single-arm phase 2 clinical trial of mitapivat for adult patients with erythrocyte membranopathies (SATISFY): a framework for interventional trials in rare anaemias – pilot study protocol

BMJ Open2024-07-019 citations

Safety and Efficacy of Mitapivat in Adult Patients with Erythrocyte Membranopathies (SATISFY)

Blood2023-11-021 citations